{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T04:36:56Z","timestamp":1767415016368,"version":"3.38.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03069-3","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T13:34:59Z","timestamp":1738416899000},"page":"188-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of anti-Xa direct oral anticoagulants vs. warfarin in patients homozygous for Factor V Leiden and prothrombin G20210A mutations"],"prefix":"10.1007","volume":"58","author":[{"given":"Ofir","family":"Dan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7711-5410","authenticated-orcid":false,"given":"Oleg","family":"Pikovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomer","family":"Kerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirly","family":"Amar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Rabinovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"issue":"07","key":"3069_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1055\/s-0037-1616237","volume":"86","author":"I Martinelli","year":"2001","unstructured":"Martinelli I (2001) Risk factors in venous thromboembolism. Thromb Haemost 86(07):395\u2013403","journal-title":"Thromb Haemost"},{"issue":"5","key":"3069_CR2","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1111\/jth.15274","volume":"19","author":"E Castoldi","year":"2021","unstructured":"Castoldi E et al (2021) Severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besan\u00e7on). J Thromb Haemost 19(5):1186\u20131199","journal-title":"J Thromb Haemost"},{"key":"3069_CR3","doi-asserted-by":"publisher","first-page":"232470962110584","DOI":"10.1177\/23247096211058486","volume":"10","author":"S Elkattawy","year":"2022","unstructured":"Elkattawy S et al (2022) Prothrombin G20210A gene mutation-induced recurrent deep vein thrombosis and pulmonary embolism: case report and literature review. J Investig Med High Impact Case Rep 10:23247096211058486","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"09","key":"3069_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1055\/s-0037-1616136","volume":"86","author":"J Emmerich","year":"2001","unstructured":"Emmerich J et al (2001) Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism. Thromb Haemost 86(09):809\u2013816","journal-title":"Thromb Haemost"},{"key":"3069_CR5","doi-asserted-by":"crossref","unstructured":"Poort SR et al (1996) A common genetic variation in the 3\u2019-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698"},{"issue":"8983","key":"3069_CR6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(95)91803-5","volume":"346","author":"DC Rees","year":"1995","unstructured":"Rees DC, Cox M, Clegg JB (1995) World distribution of factor V Leiden. Lancet (London England) 346(8983):1133\u20131134","journal-title":"Lancet (London England)"},{"key":"3069_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1538-7836.2009.03394.x","volume":"7","author":"F Rosendaal","year":"2009","unstructured":"Rosendaal F, Reitsma P (2009) Genetics of venous thrombosis. J Thromb Haemost 7:301\u2013304","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3069_CR8","first-page":"1","volume":"13","author":"JL Kujovich","year":"2011","unstructured":"Kujovich JL (2011) Factor v Leiden Thrombophilia. Genet Sci 13(1):1\u201316","journal-title":"Genet Sci"},{"issue":"12","key":"3069_CR9","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1055\/s-0037-1614912","volume":"82","author":"E Rosen","year":"1999","unstructured":"Rosen E et al (1999) High frequency of factor V Leiden in a population of Israeli arabs. Thromb Haemost 82(12):1768\u20131768","journal-title":"Thromb Haemost"},{"issue":"4","key":"3069_CR10","first-page":"1119","volume":"92","author":"A Zivelin","year":"1998","unstructured":"Zivelin A et al (1998) A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood J Am Soc Hematol 92(4):1119\u20131124","journal-title":"Blood J Am Soc Hematol"},{"issue":"2","key":"3069_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/1570163811209020083","volume":"9","author":"A G\u00f3mez-Outes","year":"2012","unstructured":"G\u00f3mez-Outes A et al (2012) Discovery of anticoagulant drugs: a historical perspective. Curr Drug Discov Technol 9(2):83\u2013104","journal-title":"Curr Drug Discov Technol"},{"issue":"6","key":"3069_CR12","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1172\/JCI117623","volume":"94","author":"B Z\u00f6ller","year":"1994","unstructured":"Z\u00f6ller B et al (1994) Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Investig 94(6):2521\u20132524","journal-title":"J Clin Investig"},{"issue":"23","key":"3069_CR13","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1182\/blood.2023023326","volume":"143","author":"J Ryu","year":"2024","unstructured":"Ryu J et al (2024) Thrombosis risk in single-and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank. Blood 143(23):2425\u20132432","journal-title":"Blood"},{"issue":"7","key":"3069_CR14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/archinte.166.7.729","volume":"166","author":"WK Ho","year":"2006","unstructured":"Ho WK et al (2006) Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 166(7):729\u2013736","journal-title":"Arch Intern Med"},{"issue":"10","key":"3069_CR15","first-page":"3329","volume":"96","author":"P Simioni","year":"2000","unstructured":"Simioni P et al (2000) Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood J Am Soc Hematol 96(10):3329\u20133333","journal-title":"Blood J Am Soc Hematol"},{"issue":"9","key":"3069_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799\u2013808","journal-title":"N Engl J Med"},{"issue":"13","key":"3069_CR17","doi-asserted-by":"publisher","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Warden BA (2020) Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Association 9(13):e017559","journal-title":"J Am Heart Association"},{"issue":"26","key":"3069_CR18","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"E Investigators","year":"2010","unstructured":"Investigators E (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499\u20132510","journal-title":"N Engl J Med"},{"issue":"15","key":"3069_CR19","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"H-V Investigators","year":"2013","unstructured":"Investigators H-V (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406\u20131415","journal-title":"N Engl J Med"},{"issue":"6","key":"3069_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199702063360601","volume":"336","author":"S Schulman","year":"1997","unstructured":"Schulman S et al (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 336(6):393\u2013398","journal-title":"N Engl J Med"},{"issue":"24","key":"3069_CR21","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342\u20132352","journal-title":"N Engl J Med"},{"key":"3069_CR22","first-page":"3724","volume":"130","author":"P Arora","year":"2017","unstructured":"Arora P et al (2017) Use of direct oral anticoagulants in inherited Thrombophilia. Blood 130:3724","journal-title":"Blood"},{"issue":"1","key":"3069_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11239-016-1428-2","volume":"43","author":"JW Skelley","year":"2017","unstructured":"Skelley JW, White CW, Thomason AR (2017) The use of direct oral anticoagulants in inherited thrombophilia. J Thromb Thrombolysis 43(1):24\u201330","journal-title":"J Thromb Thrombolysis"},{"key":"3069_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s12185-020-03012-7","volume":"113","author":"J Zuk","year":"2021","unstructured":"Zuk J et al (2021) Direct oral anticoagulants in patients with severe inherited thrombophilia: a single-center cohort study. Int J Hematol 113:190\u2013198","journal-title":"Int J Hematol"},{"issue":"12","key":"3069_CR25","first-page":"1968","volume":"124","author":"N van Es","year":"2014","unstructured":"van Es N et al (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood J Am Soc Hematol 124(12):1968\u20131975","journal-title":"Blood J Am Soc Hematol"},{"key":"3069_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.thromres.2019.12.002","volume":"185","author":"O Pikovsky","year":"2020","unstructured":"Pikovsky O et al (2020) Congenital thrombotic thrombocytopenic purpura in a large cohort of patients carrying a novel mutation in ADAMTS13 gene. Thromb Res 185:167\u2013170","journal-title":"Thromb Res"},{"issue":"8","key":"3069_CR27","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/jth.12301","volume":"11","author":"W Ageno","year":"2013","unstructured":"Ageno W et al (2013) The diagnosis of symptomatic recurrent pulmonary embolism and deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost 11(8):1597\u20131602","journal-title":"J Thromb Haemost"},{"issue":"4","key":"3069_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J 41(4):543\u2013603","journal-title":"Eur Heart J"},{"issue":"11","key":"3069_CR29","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S et al (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non\u2010surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119\u20132126","journal-title":"J Thromb Haemost"},{"issue":"03","key":"3069_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"F Rosendaal","year":"1993","unstructured":"Rosendaal F et al (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69(03):236\u2013239","journal-title":"Thromb Haemost"},{"issue":"3","key":"3069_CR31","first-page":"407","volume":"83","author":"M Al-Otaiby","year":"2021","unstructured":"Al-Otaiby M et al (2021) The prevalence of Factor V Leiden (Arg506Gln) mutation in King Khalid University Hospital patients, 2017\u20132019. Nagoya J Med Sci 83(3):407","journal-title":"Nagoya J Med Sci"},{"issue":"6","key":"3069_CR32","first-page":"486","volume":"18","author":"M Margaglione","year":"2020","unstructured":"Margaglione M et al (2020) Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study. Blood Transfus 18(6):486","journal-title":"Blood Transfus"},{"key":"3069_CR33","doi-asserted-by":"crossref","unstructured":"Serrao A et al (2019) Direct oral anticoagulants in patients affected by major congenital thrombophilia. Mediterranean J Hematol Infect Dis, 11(1)","DOI":"10.4084\/mjhid.2019.044"},{"issue":"6","key":"3069_CR34","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/MBC.0000000000000613","volume":"28","author":"A Undas","year":"2017","unstructured":"Undas A, Goralczyk T (2017) Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients. Blood Coagul Fibrinolysis 28(6):438\u2013442","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"23","key":"3069_CR35","doi-asserted-by":"publisher","first-page":"e018917","DOI":"10.1161\/JAHA.120.018917","volume":"9","author":"E Campello","year":"2020","unstructured":"Campello E et al (2020) Direct oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: a prospective cohort study. J Am Heart Association 9(23):e018917","journal-title":"J Am Heart Association"},{"key":"3069_CR36","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.thromres.2018.01.046","volume":"163","author":"CI Coleman","year":"2018","unstructured":"Coleman CI et al (2018) Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state. Thromb Res 163:132\u2013137","journal-title":"Thromb Res"},{"issue":"4","key":"3069_CR37","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jth.14398","volume":"17","author":"MA Elsebaie","year":"2019","unstructured":"Elsebaie MA et al (2019) Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. J Thromb Haemost 17(4):645\u2013656","journal-title":"J Thromb Haemost"},{"key":"3069_CR38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11239-019-01878-x","volume":"48","author":"M Giustozzi","year":"2019","unstructured":"Giustozzi M et al (2019) Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. J Thromb Thrombolysis 48:439\u2013453","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"3069_CR39","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1177\/1358863X16668588","volume":"21","author":"SZ Goldhaber","year":"2016","unstructured":"Goldhaber SZ et al (2016) Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE-COVER\u00ae, RE-COVER\u2122 II, and RE-MEDY\u2122. Vascular Med 21(6):506\u2013514","journal-title":"Vascular Med"},{"key":"3069_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s11239-019-01954-2","volume":"49","author":"R Chaudhary","year":"2020","unstructured":"Chaudhary R et al (2020) Direct oral anticoagulants: a review on the current role and scope of reversal agents. J Thromb Thrombolysis 49:271\u2013286","journal-title":"J Thromb Thrombolysis"},{"issue":"14","key":"3069_CR41","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"EP Investigators","year":"2012","unstructured":"Investigators EP (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287\u20131297","journal-title":"N Engl J Med"},{"issue":"9745","key":"3069_CR42","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","volume":"376","author":"L Wallentin","year":"2010","unstructured":"Wallentin L et al (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376(9745):975\u2013983","journal-title":"Lancet"},{"key":"3069_CR43","doi-asserted-by":"crossref","unstructured":"White HD et al (2007) Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. archives of internal medicine. 167(3):239\u2013245","DOI":"10.1001\/archinte.167.3.239"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03069-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03069-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03069-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:24:50Z","timestamp":1741307090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03069-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["3069"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03069-3","relation":{},"ISSN":["1573-742X"],"issn-type":[{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"7 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no potential conflicts of interest capable of influencing judgment on the part of any author. There is no financial relationship to any commercial entities related to the subject of the paper for all authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}